Skip to main content

Advertisement

Fig. 1 | Genome Medicine

Fig. 1

From: Acquired mechanisms of immune escape in cancer following immunotherapy

Fig. 1

The great escape: acquired mechanisms of immune evasion in cancer. Multiple immunotherapeutic approaches have potently targeted T-cell responses (T) against cancer cells (C) in the clinical setting (1); however, a substantial subset of initial responders acquire novel immunogenomic means of immune escape and relapse. From clinical investigations, the most common acquired mechanisms of immune escape appear to be (2) deficits in antigen presentation machinery, (3) loss of antigenicity, and/or (4) loss of immunogenicity—including by exploiting bypass immune checkpoint pathways

Back to article page